Bromperidol
![]() | |
| Clinical data | |
|---|---|
| Trade names | Bromidol, Bromodol |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral |
| ATC code | N05AD06 (WHO) |
| Identifiers | |
| |
| CAS Number |
10457-90-6 |
| PubChem (CID) | 2448 |
| ChemSpider |
2354 |
| UNII |
LYH6F7I22E |
| KEGG |
D01101 |
| ChEMBL |
CHEMBL28218 |
| ECHA InfoCard | 100.030.845 |
| Chemical and physical data | |
| Formula | C21H23BrFNO2 |
| Molar mass | 420.315 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
| | |
Bromperidol (marketed as Bromidol, Bromodol) is a butyrophenone derivative. It is a potent and long-acting neuroleptic, used as an antipsychotic in the treatment of schizophrenia. It was discovered at Janssen Pharmaceutica in 1966.
References
- Poldinger W, Bures E, Haage H, Clinical study with bromperidol, a new butyrophenone derivative, Int Pharmacopsychiatry. 1977;12(1):20-4.
- Dubinsky B, McGuire JL, Niemegeers CJ, Janssen PA, Weintraub HS, McKenzie BE, Bromperidol, a new butyrophenone neuroleptic: a review, Psychopharmacology (Berl). 1982;78(1):1-7.
This article is issued from Wikipedia - version of the 8/11/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
